期刊文献+

室间隔缺损合并重度肺动脉高压的诊断性治疗及远期随访 被引量:1

The application of diagnostic treatment in ventricular septal defects patients associated with severe pulmonary arterial hypertension and long-term effects
下载PDF
导出
摘要 目的:分析室间隔缺损合并重度肺动脉高压(pulmonary hypertension,PH)患者的诊断性治疗及远期随访结果,总结先天性心脏病(先心病)合并重度肺动脉高压患者的诊断性治疗体会。方法:2005年10月至2010年12月,收治室间隔缺损合并重度肺动脉高压患者65例,分别给与选择性扩张肺动脉药物治疗,以不吸氧状态下末梢氧饱和度稳定在95%以上为主要标准,判断手术指征。结果:手术54例,均在体外循环下行室间隔缺损修补术。围手术期死亡1例,无远期死亡,11例不具备手术条件,继续药物治疗。随访12~36个月,平均肺动脉压力低于40 mmHg(1 mmHg=0.133 kPa)。未手术患者肺动脉压力明显降低,心功能明显改善。结论:通过药物对重度肺动脉高压患者进行诊断性治疗,可以对肺动脉高压性质做出准确的判断,能获得良好的疗效。 Objective:To evaluate the standard of operative indications and the perioperative manage- ment of ventricular septal defect complicated with severe pulmonary hypertension. Methods: From October 2005 to December 2010, 65 patients suffered ventricular septal defect accompanying with severe pulmonary hy- pertension were given selective dilation of the pulmonary vasodilator drugs. Standard of operative indications was on the base of change of SpO2, echocardiogram and X-ray. Results : After the pre-operation preparative, 54 ca- ses operation was performed, 1 patient died in hospital. The follow-up showed that the pulmonary pressure was significantly decreased. Conclusion: Satisfactory result can be achieved in treatment of ventricular septal defect complicated with severe pulmonary hypertension by comprehensive preoperative management and preoperative a- nalysis of surgical indications.
出处 《心肺血管病杂志》 CAS 2012年第4期402-404,共3页 Journal of Cardiovascular and Pulmonary Diseases
关键词 先天性心脏病 室间隔缺损 肺动脉高压 Ventricular septal defect Pulmonary arterial hypertension Congenital heart disease
  • 相关文献

参考文献8

二级参考文献57

  • 1Singh TP,Rohit M,Grover A,菅鑫妍.口服西地那非疗法治疗严重肺动脉高压的效果研究[J].中国处方药,2006(8):29-29. 被引量:49
  • 2[1]Gaine S. Pulmonary hypertension. JAMA, 2000, 284:3160-3168.
  • 3[2]Heath D, Edwards J. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation, 1958, 18:533-547.
  • 4[3]Kidd L, Driscoll D, Gersony W, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation, 1993, 87:138-151.
  • 5[4]Vogel M, Berger F, Kramer A, et al. Incidence of se-condary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart, 1999, 82:30-33.
  • 6[5]Jeffery T K, Morrell N W. Molecular and cellular basis of pulmonary vascular remondeling in pulmonary hypertension. Prog Cardiol Dis, 2002, 45:173-202.
  • 7[6]Geiger R, Berger R M, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol, 2000, 191:202-207.
  • 8[7]Tuder R M, Cool C D, Yeager M, et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med, 2001, 22:405-418.
  • 9[8]Davie N, Haleen S J, Upton P D, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med, 2002, 165:398-405.
  • 10[9]Gries A, Bode C, Peter K, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation, 1998, 97:1481-1487.

共引文献55

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部